an OPEN Health Company

Section Links

Newsletter Signup

ISPOR 2016 - RWE round-up from pH Associates

You are currently in: Home > Latest News > ISPOR 2016 - RWE round-up from pH Associates

Date: 10/11/2016

ISPOR 2016 - RWE round-up from pH Associates, your RWE experts!


This year ISPOR was held in Vienna at the Austria Centre from the 29th October to the 2nd November. pH Associates were exhibiting at the conference along with our sister company Open Access Consulting.

The number of sessions focusing on RWE was larger than ever this year with many opinions being debated, new methods and analysis techniques being showcased along with vast numbers of posters being presented by almost 4000 delegates.

We’ve summarised some of the most interesting RWE related sessions below. Please call us if you’d like more information about any of these please contact us at pH Associates on 01628 481112.

On Sunday evening there was an educational symposia entitled; The Evolving Role of Real-World Data in Evidence Synthesis to Meet Demands for Evidence-Based Medicine where a number of experts including Olivia Wu, Deputy Director, HEHTA Research Unit, Health Economics & Health Technology Assessment, University of Glasgow and Neil Hawkins, Professor in HE and HTA, Institute of Health & Well Being, University of Glasgow, debated the benefits and disadvantages of identifying and utilising RWD for use in evidence synthesis and comparative effectiveness. They concluded with their thoughts on how such studies should be interpreted and critiqued when used to reduce uncertainty in the decision making process.

On Monday there was an interesting session on “The Biosimilar Effect: How Real-World Evidence Will Influence Adoption of Biosimilar Specialty Therapies”  where it was discussed that with a lower threshold for clinical research required for regulatory approval, RWE is critical  to defining value and allowing effective decision on use.

There was also an interesting session on whether European RWD requires a digital Schengen to support federated Access, assessment and use, opening borders at institute to allow cross country collaboration.

On Tuesday there was a session entitled “Let’s go fly a kite – managing the winds of change in Real world evidence studies” and a session on database use in outcomes research studies.

The day rounded up with an interesting session on how real world evidence can be used to support value proposition and reimbursement at launch: the aspirational meeting the impractical where a number of eminent speakers including Andrew Briggs, William R Lindsay Chair of Health Economics & Professor of Health Economics, University of Glasgow talked about the PICO framework and the widening gulf between RCTs and payer needs, concluding that RWE plays an important role for payers, allowing less uncertainly in decision making.

On Wednesday there was a fascinating session entitled “Using observational (real world) data in HTA assessment: route to confusion or better decision?”. This is something our clients ask a lot and so we listened to Sarah Garner, Associate Director of Science policy & research, NICE and Mark Sculpher, Professor of Health Economics, University of York with interest. The session saw the speakers debate the relative importance of getting more timely access to drugs for patients with having to accept uncertainties and potential bias associated with RWE. Ultimately the panel agreed that RWE is crucial, and risks can be minimised by the use of better analysis methods and / or seeking ways to incorporate routine data into RCTs.


>> To Top    >> Back